Press Releases
-
Advanced BioDesign to present preclinical proof of concept of ABD-0171 in MSS colorectal cancer at the AACR Annual Meeting 2025
Lyon, March 28th – Advanced BioDesign announced today it will present updated results of its second generation of ALDH1 inhibitor, ABD0171, at the upcoming AACR…
-
Advanced Biodesign Announces First Patient Dosed in ODYSSEY
Lyon (France), March 4, 2025 – Advanced BioDesign, a clinical-stage pharmaceutical company specializing in the development of new therapeutic approaches to resistant cancers, is pleased…
-
Advanced BioDesign is nominee as « Best StartUp » for 2024 Prix Galien USA
Advanced Biodesign has been nominated as the “Best Start-Up” at the prestigious Prix Galien USA 2024! 🏆 This nomination is a testament to our unwavering commitment to innovation and…
-
Advanced BioDesign accelerates ODYSSEY clinical trial with a new design following ABD-3001’s highly promising initial results in Acute Myeloid Leukemia
• Initial clinical data for ABD-3001 in AML have led French health authorities to approve a compassionate use program for the treatment. • Thanks to…
Advanced BioDesign 